Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 29; no. 15_suppl; p. 4588
Main Authors Templeton, A., Rothermundt, C., Cathomas, R., Baertschi, D., Droege, C., Gautschi, O., Borner, M. M., Fechter, E., Stenner, F., Winterhalder, R. C., Mueller, B., Dutoit, V., Dietrich, P., Schiess, R., Wild, P., Thalmann, G. N., Klingbiel, D., Gillessen, S.
Format Journal Article
LanguageEnglish
Published 20.05.2011
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2011.29.15_suppl.4588